 REDWOOD CITY, Calif., June 09, 2022 GLOBE NEWSWIRE -- Revolution Medicines, Inc. Nasdaq: RVMD, a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a live fireside chat at the event. 